Table 1.

Comparison of clinicopathologic characteristics of TNBC and ER⁺HER2^– RCB II/III patients whose tumors were assessed for immune infiltrates.

	TNBC (n = 80)	ER+HER2– (n = 73)
Age (median, range)	51 (26–78)	50 (33–75)
Grade (% n)
1	2.5 (n = 2)	5.5 (n = 4)
2	25 (n = 20)	64.5 (n = 47)
3	72.5 (n = 58)	30 (n = 22)
Pre-NAC tumor stage (% n)
1	5 (n = 4)	4.11 (n = 3)
2	52.5 (n = 42)	61.64 (n = 45)
3	22.5 (n = 18)	21.92 (n = 16)
4	20 (n = 16)	12.33 (n = 9)
Pre-NAC nodal stage (% n)
N0	46.25 (n = 37)	54.79 (n = 40)
N1	45 (n = 36)	41.1 (n = 30)
N2	2.5 (n = 2)	1.37 (n = 1)
N3	6.25 (n = 5)	2.74 (n = 2)
Pre-NAC stage (% n)
2a	25 (n = 20)	45.2 (n = 33)
2b	40 (n = 32)	26.0 (n = 19)
3a	11.2(n = 9)	12.3 (n = 9)
3b	15 (n = 12)	12.3 (n = 9)
3c	8.8 (n = 7)	4.1 (n = 3)
Post-NAC RCB score (% n)
RCB II	68.2 (n = 54)	62.9 (n = 45)
RCB III	31.8 (n = 25)	37.1 (n = 27)